CyGene Laboratories Receives U.S. Patent Office Notice of Allowance for next Generation Gene Therapy Technology

ARCHIVED 2002–2016: Originally distributed via the eWire press wire service. Preserved as historical record.

SUBSCRIBE/UNSUBSCRIBE |

Corporate Responsibility

Science & Technology

Syndication Partners

**************************************************************************

E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE

**************************************************************************

CyGene Laboratories Receives U.S. Patent Office Notice of Allowance for next Generation Gene Therapy Technology

CORAL SPRINGS, FLORIDA, Jul. 22 -/E-Wire/-- CyGene Laboratories, Inc. (OTC BB: CYGE.OB) announced today that the United States Patent and Trademark Office has approved and will issue a patent for the company's next generation gene-capture technology. Although developed for the highly efficient capture of genetic sequences for diagnostic purposes, the greatest commercial potential for the technology lies in its properties that allow for its use as a highly stable and efficient gene therapy drug for Antisense and RNA Interference (RNAi).

Antisense and RNAi can function to destroy and/or inhibit the reproduction of organisms such as viruses, bacteria, parasites or cancer cells and can block the production of proteins that have harmful effects on a patient. Diseases such as cancer, cardiovascular disease, autoimmune disorders, inflammatory diseases, and infectious diseases are some examples where this gene therapy could offer new hope to the effective and safe treatment of patients. Developed with distinct properties that allow the drug to resist enzymatic degradation and survive the harsh environment in the bloodstream, this next generation approach is superior to conventional gene therapy drugs which can undergo rapid degradation and elimination in the body and are not efficiently taken up into diseased cells, resulting in decreased drug efficacy.

"With today's patent notification, CyGene now has its first patent for one of two distinct platform drugs," said Martin Munzer, Chief Executive Officer, CyGene Laboratories, Inc. "Our drug candidates under development hold significant commercial applications in the areas of disease treatment and for the containment of the spread of bio-chemical warfare agents."

About CyGene Laboratories CyGene Laboratories, based in Coral Springs, Florida, is dedicated to developing its proprietary genetic profiling and diagnostic testing methods for the medical marketplace. It is the company's intention to become a global leader in broad-based biotechnology applications. Since 1995 the company has been developing proprietary and automated DNA and RNA testing systems for the screening, monitoring and diagnosis of human, veterinary and plant diseases. CyGene's Haystack ProcessingÃ platform supports the highest possible levels of sensitivity and specificity available in the field of molecular diagnostics. For more information, visit the website at www.cygenelabs.com.

Forward-Looking Statements The statements made in this press release discussing the potential of the technologies and the commercial applications of the patent are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, CyGene's raising sufficient funds to support its development, marketing efforts and corporate overhead, its ability to attract technical employees and the ability of CyGene's management to grow its business with limited assistance. CyGene Laboratories has no duty and undertakes no obligation to update such statements. You should independently investigate and fully understand all risks before making investment decisions

CyGene Laboratories, Inc.

(954) 741-7077, ext. 1373

CyGene Laboratories, Inc.

http://www.cygenelabs.com

**************************************************************************

To Transmit Your News Over E-Wire, visit http://www.ewire.com or

call 1-[REDACTED-PHONE]. E-Wire Is Broadcast To Millions Of Readers Worldwide

**************************************************************************